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P
atents by their very nature limit what
others can do, offering a period of
exclusive rights over the invention to
the patent holder in return for public disclo-
sure of information about the patented inven-
tion so that other inventors can build on it—
for example, by making a better mousetrap
out of other materials. In the case of a human
gene sequence, however, the “invention” is
the information. Consequently, disclosure of
that information does not allow others to
build on it. Gene patents, especially, limit
what can be done in the realm of scientific
research and medical care because there are
no alternatives to a patented gene in diagno-
sis, treatment, and research (1–4). When
gene patents are granted improperly and in
an overly broad manner, those problems are
compounded.
U.S. patent law requires that subject
matter be useful (5), novel (6), and non-
obvious (7) and fulfill four basic disclosure
requirements: written description, enable-
ment, best mode, and def initeness (8).
When a patent is issued, the patent holder
gains the right to exclude others from mak-
ing, using, selling, offering to sell, or
importing the invention for 20 years (9). 
Evaluating Gene Patent Claims
To gain an understanding of whether the
claims contained within issued patents cov-
ering human genetic material meet the
existing statutory requirements under U.S.
patent law (10), we undertook a multiyear
project overseen by an advisory board that
included two geneticists, two consumer
advocates, and the head of an organization
that runs a nonprofit tissue bank.
Eleven project personnel (including
lawyers, licensed members of the Patent
Bar, law students, and molecular biologists)
identified human gene patents that repre-
sented a range of genetic diseases—from
single gene to multigene disorders, from
diseases where the genetic predisposition
has been identified to those where the causal
nexuses are still being identified. We used
the term “human gene patent” to include not
only patents on complete human gene
sequences, but patents that cover any human
genetic material, such as mutations in a
gene, or diagnostic methods that utilize
human genetic material that would effec-
tively preclude the use of that material by
others. We chose genetic diseases that were
subject to public attention and for which
problems in gene patents could potentially
have an impact on research and health care.
The human gene patents were not chosen
with any expectation that they would have
problems with their claims. 
The analysis was done in a rolling fash-
ion over the period of January 2003 to May
2004, to generate a database of at least 1000
individual claims. Initially, we examined
human gene patents that dealt with the main
gene or genes associated with two multi-
genic diseases: Alzheimer’s disease and
breast cancer. We then examined four sin-
gle-gene diseases: ataxia telangiectasia,
Canavan disease, familial dysautonomia,
and hereditary hemochromatosis. We then
chose three diseases that were multigenic in
nature and whose genetic basis was less
clear, for which a number of genes have
been identif ied as playing a key role:
asthma, obesity, and schizophrenia. 
A list of human gene patents for the nine
selected genetic diseases was generated by
means of the U.S. Patent & Trademark
Office (USPTO) database, advance search
option (11). We used the USPTO Web site
because it is the publicly accessible, federal
government site that scientists and inven-
tors are expected to consult in order to
investigate whether something has been
patented or there is an application pending.
The patents that we analyzed are not an
exhaustive list of human gene patents
issued by the USPTO during this period,
owing to the rolling time frame and our spe-
cific search terms.
For our analysis, we examined 74 rele-
vant patents on human genetic material, all
of which contained multiple claims (such as
a claim over a gene or a claim over muta-
tions of that gene). Because the USPTO and
the courts examine each claim with respect
to its validity, we did so as well, assessing
the 1167 claims in the 74 patents. Where the
project personnel felt that a specific claim
did not meet one or more of the legal re-
quirements of patenta-
bility, it was deemed
problematic. These
findings are the conclu-
sions of project person-
nel and are not neces-
sarily predictive of
eventual validity deter-
minations by the courts
or the USPTO.
We found that 38%
of claims were prob-
lematic (see table on
page 1567). Some claims had multiple
problems, resulting in 677 cumulative prob-
lems within the 448 problematic claims. Of
the 677 total problems identified, written
description and enablement/utility prob-
lems were the most frequent (see f igure
page 1567). Many patents claimed far more
than what the inventor actually discovered.
Some applicants took advantage of the
redundancy of the genetic code by, for
example, claiming the sequence of a protein
within a patent and then also asserting
rights over all of the DNA sequences that
encode for that protein without describing
those DNA sequences. 
Some patents exhibited written descrip-
tion problems by claiming discoveries the
patent holder did not specifically describe.
One patent covers not only the particular
polymorphism the inventor discovered but
all other polymorphisms discovered in the
future by anyone else in a region encom-
passing over 12 mega–base pairs (Mbp). 
Other patent claims were problematic with
respect to utility. In one patent, the inventor
had shown how a polymorphism could be used
to predict asthma. The inventor additionally
claimed various uses of the polymorphism to
predict other conditions, although the inventor
did not show that the polymorphism was
linked to those conditions. 
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Another troubling issue arose where a
claim was drafted disclosing only a correla-
tion between two things, often the presence of
an isoform or mutation and some multigenic
disorder or a disorder having a genetic com-
ponent. In some cases, the patent holder did
not describe how the correlation was used to
predict the disease. One such patent claims a
method of detecting whether a subject is at
increased risk of developing late-onset
Alzheimer’s disease, comprising directly or
indirectly detecting the presence or absence
of a particular protein isoform. The claim
does not account for other factors that relate
to a person’s developing Alzheimer’s disease
and does not indicate the specific relation
between the presence of the isoform and the
increased risk, but merely provides that there
is a correlation. In fact, even where a patient
does not have the isoform, he or she could
still develop the disease, and those with the
isoform might never develop the disease. The
“indirect” detection method is also vague
enough that it could include any diagnosis
based on external factors as well, such as
memory loss (a diagnostic method that was
not invented by the patent applicant). 
We also found patent claims that suffered
from one or more problems but were saved
from being classified as problematic by the
drafting language. For example, one claim
reads, “(t)he method of claim 1, 2, or 3,
wherein the method fur-
ther comprises amplify-
ing the sequence-altered
PAH DNA by use of the
polymerase chain reac-
tion (PCR).” Two of the
three referenced claims
were problematic. Claim
1 had written description,
enablement/utility, and
novelty/nonobviousness




claim was not problem-
atic, however, because it
referenced claim 2,
which contained no
problems with any of the
established categories. This language may
create a chilling effect on researchers who
want to use methods listed in claims 1 and 3
of the patent, but do not realize that the patent
is open to challenge as not validly covering
those methods.
Discussion 
Prior studies have found that gene patents
have the potential to deter medical research
and health care (12, 13). A variety of policy
alternatives are being considered to remedy
these negative effects. These include ban-
ning patents on genes entirely or narrowing
their scope, exempting researchers and diag-
nosticians from the reach of the patents, cre-
ating a system of either patent pools or com-
pulsory licensing, recognizing the rights of
third parties to oppose the granting of a par-
ticular gene patent, and allowing the people
who are the sources of the patented genes to
have a greater say in their use (4). 
Another avenue may be to have the
USPTO remedy internal problems that lead
to the issuance of gene patents that arguably
do not comply with existing patent law. This
is not a new problem or one that is specific to
gene patents (14, 15). As with any new tech-
nology, the USPTO must have competent
patent examiners to guarantee that patents
are not issued that are overly broad or overar-
ching. For example, examiners in the newly
created business method patent category
were criticized in the late 1990s for granting
poor-quality, overbroad
patents lacking novelty,






within the patent office
may not be familiar with
DNA-based technolo-
gies, one potential rem-
edy may be more train-
ing or special selection





should be reviewed by
the USPTO with different levels of scrutiny,
depending on how much social cost they
entail (14). Reports indicate that on aver-
age, the total time spent by a patent exam-
iner on a patent application is about 18
hours (16). With gene patent applications
often involving extensive biological
sequence information for each individual
claim, it may be that adequate time is not
being invested in thoroughly investigating
the patentability of the claimed material.
Where the enforcement of a patent has the
potential to be so costly to society in terms
of medical research, health care, and down-
stream innovation because there are no ade-
quate substitutes, safeguards could be
installed to ensure that the application is
examined more closely (14). 
The USPTO could also revamp financial
incentives to promote decisions based on
the quality of patents rather than their quan-
tity. Currently, patent examiners are encour-
aged with monetary bonuses to grant patent
applications, a policy that has the unsettling
effect of rewarding examiners for quickly
pushing patents through the patent office.
Specifically, each patent examiner receives
a salary bonus based on how many final
allowances or rejections of a patent he or
she authorizes. Because a rejection can be
challenged and may not become final for
quite some time, it is easier to receive a
bonus by allowing patents (14). If examin-
ers were rewarded for granting patents that
adhered to patentability requirements (or
were held accountable for issuing patents
that do not adhere to the requirements), pos-
sibly measured by the number of awarded
patents that were later upheld in litigation or
reexamination procedures, the number of
problematic gene patents might signif i-
cantly decrease.
Whether through amendments to the
patent law, alternative licensing mecha-
nisms, or policy changes in the USPTO
itself, something needs to be done about the
number of human gene patents being
granted that arguably do not measure up to
the federal patent law.
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